China Conditionally Approves MSD's Molnupiravir for COVID-19 Treatment

by Grace Wang Jan 05, 2023

On Dec. 29, 2022, China National Medical Products Administration (NMPA) conditionally approved Merck Sharp & Dohme (MSD)’s Molnupiravir Capsules (brand name: Lagevrio) for COVID-19 treatment. 

The antiviral small-molecule drug is approved for treating patients who have mild-to-moderate COVID-19 infections and high risks to develop into severe conditions. The risks can be advanced age, obesity or overweightness, chronic kidney disease, diabetes, severe cardiovascular disease, chronic obstructive pulmonary disease (COPD), active cancer, etc. 

MSD has authorized Sinopharm Group with the exclusive right to import and sell Lagevrio in the mainland Chinese market.

Lagevrio’s price in China has not been revealed. In the US, one course costs 700 USD (circa 4,818 yuan).

So far, China NMPA has approved four COVID-19 treatments:


Administration Route

Marketing Authorization Holder

Approval Date

Price for One Course

Amubarvimab/Romlusevimab Combination Therapy (BRII-196/BRII-198)


Brii Biosciences

Dec. 8, 2021

Brii Biosciences revealed the price scope: 10,000 yuan

Nirmatrelvir Tablets and Ritonavir Tablets (Paxlovid)



Feb 11, 2022

2,300 yuan

Azvudine Tablets


Genuine Biotech

July 25, 2022

540 yuan

Molnupiravir Capsules (Lagevrio)



Dec. 29, 2022

Not revealed


-       China's First Homegrown COVID-19 Pill, Azvudine, is Priced at 270 Yuan Per Bottle

-       China Approves Pfizer's Paxlovid, Encouraging COVID-19 Drug Development

Grace Wang
ChemLinked Regulatory Analyst & Editor
Copyright: unless otherwise stated all contents of this website are ©2023 - REACH24H Consulting Group - All Rights Reserved - For permission to use any content on this site, please contact
You May Also Like
Most Popular